Kura Oncology, Inc. (NASDAQ: KURA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML [Yahoo! Finance]
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
2 Incredible Growth Stocks to Buy Hand Over Fist [Yahoo! Finance]